Aclaris Therapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDAclaris Therapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 89), indicating clear outperformance against the broad market. Earnings contraction of 25% provides fundamental context to the price action. Investors should exercise caution due to high volatility (97% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $4.46 | +8.64% | ABOVE |
| 50 SMA | $4.45 | +8.70% | ABOVE |
| 100 SMA | $3.97 | +21.84% | ABOVE |
| 150 SMA | $3.65 | +32.55% | ABOVE |
| 200 SMA | $3.26 | +48.68% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ACRS in an uptrend right now?
ACRS has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, ACRS is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is ACRS overbought or oversold?
ACRS's RSI (14) is 52. The stock is in neutral territory, neither overbought nor oversold.
Is ACRS outperforming the market?
ACRS has a Relative Strength (RS) Rating of 89 out of 99. Yes, ACRS is a market leader, outperforming 89% of all stocks over the past 12 months.
Where is ACRS in its 52-week range?
ACRS is trading at $4.84, which is 94% of its 52-week high ($5.15) and 92% above its 52-week low ($1.34).
How volatile is ACRS?
ACRS has a Beta of 0.53 and 52-week volatility of 97%. It's less volatile than the S&P 500 - generally more stable.